Literature DB >> 19628670

Indirect regulation of PTH by estrogens may require FGF23.

Natalia Carrillo-López1, Pablo Román-García, Ana Rodríguez-Rebollar, José Luis Fernández-Martín, Manuel Naves-Díaz, Jorge B Cannata-Andía.   

Abstract

The mechanisms by which estrogens modulate PTH are controversial, including whether or not estrogen receptors (ERs) are present in the parathyroid glands. To explore these mechanisms, we combined a rat model of CKD with ovariectomy and exogenous administration of estrogens. We found that estrogen treatment significantly decreased PTH mRNA and serum levels. We did not observe ERalpha or ERbeta mRNA or protein in the parathyroids, suggesting an indirect action of estrogens on PTH regulation. Estrogen treatment significantly decreased serum 1,25(OH)(2) vitamin D(3) and phosphorus levels. In addition, estrogens significantly increased fibroblast growth factor 23 (FGF23) mRNA and serum levels. In vitro, estrogens led to transcriptional and translational upregulation of FGF23 in osteoblast-like cells in a time- and concentration-dependent manner. These results suggest that estrogens regulate PTH indirectly, possibly through FGF23.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19628670      PMCID: PMC2736770          DOI: 10.1681/ASN.2008121258

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  51 in total

Review 1.  Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.

Authors:  S C Manolagas
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Estrogen induces retinoid receptor expression in mouse cervical epithelia.

Authors:  G Celli; N Darwiche; L M De Luca
Journal:  Exp Cell Res       Date:  1996-08-01       Impact factor: 3.905

4.  The parathyroid is a target organ for FGF23 in rats.

Authors:  Iddo Z Ben-Dov; Hillel Galitzer; Vardit Lavi-Moshayoff; Regina Goetz; Makoto Kuro-o; Moosa Mohammadi; Roy Sirkis; Tally Naveh-Many; Justin Silver
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

5.  Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts.

Authors:  Takashi Nakamura; Yuuki Imai; Takahiro Matsumoto; Shingo Sato; Kazusane Takeuchi; Katsuhide Igarashi; Yoshifumi Harada; Yoshiaki Azuma; Andree Krust; Yoko Yamamoto; Hiroshi Nishina; Shu Takeda; Hiroshi Takayanagi; Daniel Metzger; Jun Kanno; Kunio Takaoka; T John Martin; Pierre Chambon; Shigeaki Kato
Journal:  Cell       Date:  2007-09-07       Impact factor: 41.582

6.  Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers.

Authors:  F Cosman; V Shen; F Xie; M Seibel; A Ratcliffe; R Lindsay
Journal:  Ann Intern Med       Date:  1993-03-01       Impact factor: 25.391

Review 7.  Combination therapy for treatment of osteoporosis: A review.

Authors:  Joann V Pinkerton; Alan C Dalkin
Journal:  Am J Obstet Gynecol       Date:  2007-12       Impact factor: 8.661

Review 8.  Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism.

Authors:  Arnold J Felsenfeld; Mariano Rodríguez; Escolástico Aguilera-Tejero
Journal:  Clin J Am Soc Nephrol       Date:  2007-10-17       Impact factor: 8.237

9.  Aromatase deficiency causes altered expression of molecules critical for calcium reabsorption in the kidneys of female mice *.

Authors:  Orhan K Oz; Asghar Hajibeigi; Kevin Howard; Carolyn L Cummins; Monique van Abel; Rene Jm Bindels; R Ann Word; Makoto Kuro-o; Charles Y C Pak; Joseph E Zerwekh
Journal:  J Bone Miner Res       Date:  2007-12       Impact factor: 6.741

10.  Effects of estradiol, calcitriol and both treatments combined on bone histomorphometry in rats with chronic kidney disease and ovariectomy.

Authors:  M Naves Díaz; A Rodríguez Rodríguez; J L Fernández Martín; M Serrano Arias; P Menéndez Rodríguez; J B Cannata Andía
Journal:  Bone       Date:  2007-07-17       Impact factor: 4.398

View more
  31 in total

1.  Associations of estradiol and testosterone with serum phosphorus in older men: the Osteoporotic Fractures in Men study.

Authors:  Jerry Meng; Claes Ohlsson; Gail A Laughlin; Michel Chonchol; Christina L Wassel; Osten Ljunggren; Magnus K Karlsson; Dan Mellstrom; Eric S Orwoll; Elizabeth Barrett-Connor; Joachim H Ix
Journal:  Kidney Int       Date:  2010-06-09       Impact factor: 10.612

2.  Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women.

Authors:  Koji Fujita; Matthew M Roforth; Susan Demaray; Ulrike McGregor; Salman Kirmani; Louise K McCready; James M Peterson; Matthew T Drake; David G Monroe; Sundeep Khosla
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

3.  Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.

Authors:  Itsuo Gorai; Shin Hattori; Yaku Tanaka; Yasuhisa Iwaoki
Journal:  J Bone Miner Metab       Date:  2011-12-02       Impact factor: 2.626

Review 4.  Regulation and function of the FGF23/klotho endocrine pathways.

Authors:  Aline Martin; Valentin David; L Darryl Quarles
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

5.  Association of serum inorganic phosphate with sex steroid hormones and vitamin D in a nationally representative sample of men.

Authors:  W Wulaningsih; M Van Hemelrijck; K Michaelsson; N Kanarek; W G Nelson; J H Ix; E A Platz; S Rohrmann
Journal:  Andrology       Date:  2014-10-01       Impact factor: 3.842

6.  Association of serum phosphorus with left ventricular mass in men and women with stable cardiovascular disease: data from the Heart and Soul Study.

Authors:  Georges Saab; Mary A Whooley; Nelson B Schiller; Joachim H Ix
Journal:  Am J Kidney Dis       Date:  2010-06-26       Impact factor: 8.860

7.  Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study.

Authors:  Joachim H Ix; Michel Chonchol; Gail A Laughlin; Michael G Shlipak; Mary A Whooley
Journal:  Am J Kidney Dis       Date:  2011-08-19       Impact factor: 8.860

8.  Klotho/fibroblast growth factor 23- and PTH-independent estrogen receptor-α-mediated direct downregulation of NaPi-IIa by estrogen in the mouse kidney.

Authors:  Rose Webster; Sulaiman Sheriff; Rashma Faroqui; Faraaz Siddiqui; John R Hawse; Hassane Amlal
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-18

9.  Functional heterogeneity of osteocytes in FGF23 production: the possible involvement of DMP1 as a direct negative regulator.

Authors:  Ji-Won Lee; Akira Yamaguchi; Tadahiro Iimura
Journal:  Bonekey Rep       Date:  2014-06-04

Review 10.  FGF-23 and secondary hyperparathyroidism in chronic kidney disease.

Authors:  Justin Silver; Tally Naveh-Many
Journal:  Nat Rev Nephrol       Date:  2013-07-23       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.